[1]Foltynie T. Glycolysis as a therapeutic target for Parkinson’s disease [J]. Lancet Neurol, 2019, 18(12):1072-1074.
[2]Müller MLTM, Marusic U, van Emde Boas M, et al. Treatment options for postural instability and gait difficulties in Parkinson’s disease [J]. Expert Rev Neurother, 2019, 19(12):1229-1251.
[3]Peng LH, Sun CN, Guan NN, et al. HNMDA: heterogeneous network-based miRNA-disease association prediction [J]. Mol Genet Genomics, 2018, 293(4):983-995.
[4]Lu Q, Wu R, Zhao M, et al. miRNAs as therapeutic targets in inflammatory disease[J]. Trends Pharmacol Sci, 2019,40(11):853-865.
[5]Wu DM, Wang S, Wen X, et al. Suppression of microRNA-342-3p increases glutamate transporters and prevents dopaminergic neuron loss through activating the Wnt signaling pathway via p21-activated kinase 1 in mice with Parkinson’s disease [J]. J Cell Physiol, 2019, 234(6):9033-9044.
[6]Wang Y, Cai Y, Huang H, et al. miR-486-3p Influences the neurotoxicity of a-synuclein by targeting the SIRT2 gene and the polymorphisms at target sites contributing to Parkinson’s disease[J]. Cell Physiol Biochem, 2018, 51(6):2732-2745.
[7]Li ShZ. Research on the mechanism of microRNA-7 inhibiting MPP+-induced apoptosis in Parkinson’s cell model through Bax and sirt2[D]. Zhengzhou :Zhengzhou University, 2016.(in Chinese)
李世泽. MicroRNA-7通过Bax和sirt2抑制MPP+诱导的帕金森细胞模型凋亡机制研究[D].郑州:郑州大学,2016.
[8]Blaybel R, Théoleyre O, Douablin A, et al. Downregulation of the Spi-1/PU.1 oncogene induces the expression of TRIM10/HERF1, a key factor required for terminal erythroid cell differentiation and survival [J]. Cell Res, 2008,18(8):834-845.
[9]Huang Q, Zhu X, Xu M. Silencing of TRIM10 alleviates apoptosis in cellular model of Parkinson’s disease [J]. Biochem Biophys Res Commun, 2019,518(3):451-458.
[10] Han QQ, Wang GQ, Gu XF. Detection of intestinal microbial changes in rotenoneinduced Parkinson’s disease model mice[J].Acta Anatomica Sinica,2020,51(4):507-512. (in Chinese)
韩秋琴,万国庆,顾雪锋.鱼藤酮诱导帕金森病模型小鼠体内肠道微生物的变化[J].解剖学报,2020,51(4):507-512.
[11]Shao QH, Chen Y, Li FF, et al. TLR4 deficiency has a protective effect in the MPTP/probenecid mouse model of Parkinson’s disease [J]. Acta Pharmacol Sin, 2019, 40(12):1503-1512.
[12]Li T, Zhang W, Kang X, et al. Salidroside protects dopaminergic neurons by regulating the mitochondrial MEF2D-ND6 pathway in the MPTP/MPP+ -induced model of Parkinson’s disease[J]. J Neurochem, 2020,153(2):276-289.
[13]Cantelmo RA, Dos Santos NAG, Dos Santos AC, et al. Dual effects of S-adenosyl-methyonine on PC12 cells exposed to the dopaminergic neurotoxin MPP [J]. J Pharm Pharmacol, 2020, 72(10):1427-1435.
[14]Ba RQ, Liu J, Fan XJ, et al. Effects of miR-199a on autophagy by targeting glycogen synthase kinase 3β to activate PTEN/AKT/mTOR signaling in an MPP+in vitro model of Parkinson’s disease[J]. Neurol Res, 2020, 42(4):308-318.
[15]Zheng M, Liu C, Fan Y, et al. Protective effects of paeoniflorin against MPP(+)-induced neurotoxicity in PC12 cells[J]. Neurochem Res, 2016,41(6):1323-1334.
[16]Choi YH. Isorhamnetin induces ROS-dependent cycle arrest at G2/M phase and apoptosis in human hepatocarcinoma Hep3B cells [J]. Gen Physiol Biophys, 2019,38(6):473-484.
[17]Wang BW, Jiang Y, Yao ZL, et al. Aucubin protects chondrocytes against IL-1β-induced apoptosis in vitro and inhibits osteoarthritis in mice model [J]. Drug Des Devel Ther, 2019, 13(9):3529-3538.
[18]Bofill-De Ros X, Yang A, Gu S. Isomirs: expanding the miRNA repression toolbox beyond the seed [J]. Biochim Biophys Acta Gene Regul Mech, 2020, 1863(4):194373-194383.
[19]Zhang J, Zhou D, Zhang Z, et al. miR-let-7a suppresses α-synuclein-induced microglia inflammation through targeting STAT3 in Parkinson’s disease [J]. Biochem Biophys Res Commun, 2019, 519(4):740-746.
[20]Liu Y, Chen D, Hou CL, et al. Ubiquitin E3 ligase TRIM10 aggravates myocardial hypoxia/reoxygenation injury through JNK/P38MAPK signaling pathway[J].Journal of Cardiovascular and Pulmonary Diseases, 2019,38(5):566-572.(in Chinese)
刘洋,陈东,侯翠柳,等. 泛素E3连接酶TRIM10在心肌细胞缺氧/复氧损伤的作用及机制[J].心肺血管病杂志,2019,38(5):566-572.
|